Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.

ABSTRACT:

Background

Aggressive B cell lymphoma with secondary central nervous system (CNS) involvement (SCNSL) carries a dismal prognosis. Chimeric antigen receptor (CAR) T cells (CAR-T) targeting CD19 have revolutionized the treatment for B cell lymphomas; however, only single cases with CNS manifestations successfully treated with CD19 CAR-T have been reported.

Methods

We prospectively enrolled 4 patients with SCNSL into our study to assess clinical responses and monitor T cell immunity.

Results

Two of four SNCSL patients responded to the CD19-targeted CAR-T. Only one patient showed a substantial expansion of peripheral (PB) CAR-T cells with an almost 100-fold increase within the first week after CAR-T. The same patient also showed marked neurotoxicity and progression of the

SUBMITTER: Kline K 

PROVIDER: S-EPMC10864416 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature